PMID: 6986247Mar 1, 1980Paper

Methadone use in patients with chronic renal disease

Drug and Alcohol Dependence
M J KreekM Hecht

Abstract

Methadone disposition was studied in three patients receiving chronic methadone treatment and having chronic renal disease: one oliguric patient during peritoneal dialysis, one anuric patient on hemodialysis, and one patient following renal transplantation. In all three patients plasma levels of methadone remained within the desired therapeutic range (0.09--0.68 microgram/ml) for the doses received (40-50 mg/day). Elimination of methadone and its metabolites was almost exclusively by the fecal route in the anuric patient. Less than 1% of the daily dose was removed by peritoneal dialysis or hemodialysis. There was no laboratory or clinical evidence for accumulation of either methadone or its metabolites, suggesting that methadone is an appropriate narcotic to use in patients with renal disease.

References

Jan 1, 1978·Annals of the New York Academy of Sciences·M J Kreek
Mar 1, 1978·Drug and Alcohol Dependence·R B RubensteinC L Gutjahr
Jan 1, 1976·Annals of the New York Academy of Sciences·M J KreekF H Field
May 13, 1976·The New England Journal of Medicine·M J KreekL M Giusti
Oct 1, 1966·Archives of Internal Medicine·V P DoleM J Kreek
Jan 1, 1973·Proceedings of the National Academy of Sciences of the United States of America·V P Dole, M J Kreek
Feb 5, 1973·JAMA : the Journal of the American Medical Association·M J Kreek
May 5, 1972·Science·G D Olsen
Jun 3, 1971·The New England Journal of Medicine·L Inselman

❮ Previous
Next ❯

Citations

Jan 1, 1984·Addictive Behaviors·S M HallM Kushner
Jul 1, 1996·Disease-a-month : DM·R L BarkinS J Barkin
Aug 6, 2003·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Manjula KurellaGlenn M Chertow
Aug 10, 2000·Anesthesiology Clinics of North America·M T Carney, D E Meier
Jan 1, 1997·European Journal of Pain : EJP·S Mercadante
Apr 22, 2010·Journal of Addictive Diseases·Mary Jeanne KreekBrenda Ray
Dec 22, 2007·Journal of Palliative Medicine·Sara Nicola Davison
Aug 22, 2008·Journal of Palliative Medicine·Shiho Ito, Solomon Liao
Oct 15, 2009·Journal of Palliative Medicine·Suresh ReddyEduardo Bruera
Apr 25, 2001·Journal of Addictive Diseases·E T MoolchanD Epstein
Nov 1, 1983·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·W M BennettI Singer
Apr 1, 1994·Mayo Clinic Proceedings·J E Hammack, C L Loprinzi
Nov 15, 2015·Journal of Medical Toxicology : Official Journal of the American College of Medical Toxicology·E Salsitz, T Wiegand
Oct 8, 2008·Annals of the New York Academy of Sciences·Paul J Christo, Danesh Mazloomdoost
Feb 13, 2014·Seminars in Dialysis·Sara N DavisonFrank Brennan
Jul 13, 2005·Advances in Chronic Kidney Disease·Sara N Davison
Mar 18, 2005·The Journal of Pain : Official Journal of the American Pain Society·Vincent Launay-VacherGilbert Deray
Jun 12, 2016·Journal of Critical Care·Jessica L ElefritzMichael R Lyaker
Apr 17, 2015·Seminars in Dialysis·Ameet KarambelkarPaul M Palevsky
May 13, 2015·Clinical Therapeutics·Mimi Stokke OpdalPeter Krajci
Jul 2, 2009·Mayo Clinic Proceedings·Howard S Smith
Feb 1, 1993·Pain·R FainsingerE Bruera
Sep 21, 2016·Expert Opinion on Drug Safety·Ada OffurumTanisha Gooden
May 1, 2008·The American Journal of Hospice & Palliative Care·Shalini Chhabra, Janet Bull
Mar 6, 2019·Clinical Journal of the American Society of Nephrology : CJASN·Sara N Davison
Mar 22, 1986·British Medical Journal·G J BeckerP Kincaid-Smith
Mar 12, 2002·The American Journal of Hospice & Palliative Care·W L Wheeler, E D Dickerson
Oct 1, 1987·Drug Intelligence & Clinical Pharmacy·G L Chan, G R Matzke
Dec 24, 2013·F1000Research·Malvinder S Parmar, Kamalpreet S Parmar
Nov 23, 2017·Frontiers in Pharmacology·Marta MichalskaPhilipp Wolf
Jul 5, 2018·The Journal of Pediatric Pharmacology and Therapeutics : JPPT : the Official Journal of PPAG·Amanda ReisAadil Kakajiwala
Nov 28, 2019·Pain Research & Management : the Journal of the Canadian Pain Society = Journal De La Société Canadienne Pour Le Traitement De La Douleur·Rupam RuchiSanjeev Kumar
Jun 22, 2020·CNS Drugs·Denise Kreutzwiser, Qutaiba A Tawfic
Apr 1, 2009·NDT Plus·Phuong-Chi T PhamPhuong-Thu T Pham
Sep 29, 2020·Therapeutics and Clinical Risk Management·Flaminia ColuzziPatrizia Romualdi
Feb 25, 2021·Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [et Al.]·Paul J GruberHeidi B Donnelly
Oct 9, 2021·Nature Reviews. Nephrology·Daniel G TobinUNKNOWN HOPE Consortium
Jun 12, 2020·Kidney Diseases·Mena RaoufJeffrey J Fudin

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association
V FurlanA M Taburet
Journal of Pain and Symptom Management
N BabulN A Hagen
Journal of Pain and Symptom Management
N A HagenC E Inturrisi
© 2021 Meta ULC. All rights reserved